Concepedia

Hank H. Yang

HH

Statistics

Publications

6

Citations

745

H-Index

6

Active since

2003

Affiliations

Cedars-Sinai Medical Center(Current)

Institute for Myeloma & Bone Cancer Research

Oncotherapeutics (United States)

Millennium Engineering and Integration (United States)

Medical Research Associates

Hank H. Yang is an author at Cedars-Sinai Medical Center specializing in multiple myeloma treatment, multiple myeloma, and medicine.

Publications per year

2003–2011

6

Publications

6

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Hans Mark, Hank H. Yang, Kimberly M. Parker et al. · PubMed · 2003 · 418 citations

Medicine, Oncology, Pharmacology +13

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

James R. Berenson, Hank H. Yang, Karen Sadler et al. · Journal of Clinical Oncology · 2006 · 212 citations

Medicine, Pharmacology, Pharmacotherapy +15

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

James R. Berenson, Hank H. Yang, Robert Vescio et al. · Annals of Hematology · 2008 · 43 citations

Medicine, Hematology, Oncology +17

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients

James R. Berenson, Ori Yellin, Chien‐Shing Chen et al. · British Journal of Haematology · 2011 · 31 citations

Medicine, Pharmacology, Pharmacotherapy +17

A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma

Hank H. Yang, Robert Vescio, David P. Schenkein et al. · Clinical Lymphoma · 2003 · 22 citations

Medicine, Oncology, Pharmacology +17

1–5 of 6